Amicus Therapeutics, Inc. (FOLD)
Apr 27, 2026 - FOLD was delisted (reason: acquired by BMRN)
14.49
0.00 (0.00%)
Inactive · Last trade price on Apr 24, 2026
Amicus Therapeutics Employees
Amicus Therapeutics had 511 employees as of December 31, 2025. The number of employees increased by 12 or 2.40% compared to the previous year.
Employees
511
Change (1Y)
12
Growth (1Y)
2.40%
Revenue / Employee
$1,241,115
Profits / Employee
-$53,053
Market Cap
4.55B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 511 | 12 | 2.40% |
| Dec 31, 2024 | 499 | -18 | -3.48% |
| Dec 31, 2023 | 517 | 33 | 6.82% |
| Dec 31, 2022 | 484 | -12 | -2.42% |
| Dec 31, 2021 | 496 | 13 | 2.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
FOLD News
- 2 months ago - Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications - Business Wire
- 3 months ago - Amicus Therapeutics Proxy statement: Proxy Filing - Filings
- 3 months ago - Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 3 months ago - Amicus Therapeutics Annual report: Q4 2025 - Filings
- 3 months ago - Amicus Therapeutics Earnings release: Q4 2025 - Filings
- 3 months ago - Amicus Therapeutics Slides: Q4 2025 - Filings
- 3 months ago - Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - GlobeNewsWire
- 3 months ago - Amicus Therapeutics Proxy statement: Proxy Filing - Filings